Related Experiment Video

Updated: Aug 25, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling

Xiaodong Li1,2, Ningbo Pang3, Yingcong Chen1,2

  • 1Precision Medicine Center, The Affiliated Lihuili Hospital of Ningbo University, 57 Xingning Road, Ningbo, 315000, China.

Apoptosis : an International Journal on Programmed Cell Death
|August 23, 2026
PubMed

Insights

Alantolactone (ATL) inhibits T-cell lymphoma (TCL) growth and enhances chemotherapy sensitivity. This compound shows potential for TCL immunotherapy by promoting macrophage phagocytosis.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • T-cell lymphoma (TCL) is a significant clinical challenge with unclear pathogenesis and limited effective treatments.
  • Alantolactone (ATL), a semi-terpene lactone, has shown therapeutic potential in other conditions but its role in TCL is unexplored.

Purpose of the Study:

  • To investigate the anti-cancer effects of Alantolactone (ATL) on T-cell lymphoma (TCL).
  • To explore the underlying mechanisms of ATL's action in TCL, including its impact on signaling pathways and drug sensitivity.

Main Methods:

  • In vitro studies on TCL cell proliferation, migration, and apoptosis.
  • In vivo xenograft models to assess anti-tumor efficacy and toxicity.
  • Multi-omics analysis to elucidate molecular mechanisms, including signaling pathway regulation and CD47 expression.

Main Results:

  • ATL significantly inhibited TCL cell proliferation and migration while inducing apoptosis in vitro.
  • ATL demonstrated significant anti-tumor effects in vivo with no obvious toxicity.
  • ATL enhanced TCL cell sensitivity to decitabine and other chemotherapeutic agents.
  • Mechanistically, ATL suppressed PI3K/AKT and ERK signaling, downregulating CD47 via c-Myc, thereby enhancing macrophage phagocytosis.

Conclusions:

  • Alantolactone (ATL) exhibits potent anti-TCL activity both in vitro and in vivo.
  • ATL holds promise as a novel therapeutic agent for T-cell lymphoma, potentially in combination therapies and immunotherapy.
Keywords:
AlantolactoneCD47DecitabineERKPI3K/AKTT-cell lymphomac-Myc

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...